ASH 2024 | Updated results from a Phase I/II trial of golcadomide ± rituximab in R/R FL

Yeah, the CC-99282 or golcadomide is a CELMoD or a novel immunomodulatory drug that is similar to lenalidomide, however it has a better inhibition of aiolos, which is the most important marker for the transcription factor of proliferation. So it has 100% inhibition as opposed to lenalidomide that is about 25%. So this study actually focused on high-risk patients with follicular lymphoma, median lines of therapy of four lines. Many patients had post-CAR-T status or also bispecific antibodies. So in these patients patients were exposed to lenalidomide as well so were lenalidomide treated too. In this patient population we see a high response rate at almost 80%, almost 60% CR rate, in heavily treated patients. Still data is immature for progression-free survival because it’s a follicular lymphoma but we were encouraged by the results. In terms of safety, it was pretty safe. I think the most important side effect from this combination was neutropenia. And some were grade 3 or grade 4 neutropenias that were treated with growth factors. So I think in conclusion, this is a very active combination, you know, golcadomide and rituximab. It kind of fills the gap as well in terms of the treatment for follicular lymphoma that is shifting towards bispecific antibodies, CAR T-cell therapy but the problem that we have to access distance to cancer centers patients that are unable to do CAR-T or bispecific because of fitness as well so it kind of fills the gap on that population. Physicians can keep their patients closer to their home to their clinics and treat these patients with an effective regimen so I think it adds into the armamentarium for follicular lymphoma.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.